<unk>  acts as a non-selective agonist of the dopamine D1, D2, D3, and, to a lesser extent, D4 and D5 receptors, with highest affinity for the D3 receptor. In terms of affinity,<unk>  has 10-fold selectivity for the D3 receptor over the D2, D4, and D5 receptors and 100-fold selectivity for the D3 receptor over the D1 receptor. In functional studies however,<unk>  behaves as a full agonist of D1, D2, and D3 with similar potencies (EC50). Its ability to activate both D1-like and D2-like receptors is similar to the case of apomorphine (which notably has greater efficacy in the treatment of Parkinson's disease than D2-like-selective agonists but has suboptimal pharmacokinetic properties) and pergolide but unlike pramipexole and ropinirole.<unk>  possesses the following in vitro receptor binding profile: * D1 receptor (Ki = 83 nM) * D2 receptor (Ki = 13.5 nM) * D3 receptor (Ki = 0.71 nM) * D4.2 receptor (Ki = 3.9 nM) * D4.4 receptor (Ki = 15 nM) * D4.7 receptor (Ki = 5.9 nM) * D5 receptor (Ki = 5.4 nM) * α1A-adrenergic receptor (Ki = 176 nM) * α1B-adrenergic receptor (Ki = 273 nM) * α2A-adrenergic receptor (Ki = 338 nM) * α2B-adrenergic receptor (Ki = 27 nM) * α2C-adrenergic receptor (Ki = 135 nM) * 5-HT1A receptor (Ki = 30 nM) * 5-HT7 receptor (Ki = 86 nM) * H1 receptor (Ki = 330 nM) All affinities listed were assayed using human materials except that for α2B-adrenergic which was done with NG 108–15 cells.<unk>  behaves as a partial or full agonist (depending on the assay) at all dopamine receptors listed, as an antagonist at the α2B-adrenergic receptor, and as a partial agonist at the 5-HT1A receptor. Though it has affinity for a large number of sites as shown above, at clinical doses<unk>  behaves mostly as a selective D1-like (D1, D5) and D2-like (D2, D3, D4) receptor agonist, with its α2B-adrenergic and 5-HT1A activity also possibly having some minor relevance.
Rotigotine
Tiotixene
Seltorexant
Toremifene
Daridorexant
Tetryzoline
Nyasol
Mitapivat